Pegylated doxorubicin for primary cutaneous T cell lymphoma: a report on ten patients with follow-up.
Wollina
U
U
Department of Dermatology and Allergology, Friedrich Schiller University of Jena, Germany. Wollina-Uw@khdf.de
Graefe
T
T
Kaatz
M
M
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008081:Liposomes; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D012878:Skin Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D008081:Liposomes; D011092:Polyethylene Glycols; D004317:Doxorubicin